-
4 weeks ago | 
hcplive.com | Connor Iapoce
Cardiac deaths have surged since the COVID-19 pandemic began in 2020, with sharper seasonal spikes and more deaths occurring at home, a new study finds.1A team of investigators from Mass General Brigham analyzed death certificate data from nearly 128,000 individuals who died in Massachusetts, finding that cardiac deaths exceeded expected levels between 2020 and 2023.
-
4 weeks ago | 
consultantlive.com | Connor Iapoce
Cardiac deaths have surged since the COVID-19 pandemic began in 2020, with sharper seasonal spikes and more deaths occurring at home, a new study finds.1A team of investigators from Mass General Brigham analyzed death certificate data from nearly 128,000 individuals who died in Massachusetts, finding that cardiac deaths exceeded expected levels between 2020 and 2023.
-
1 month ago | 
hcplive.com | Connor Iapoce
The US Food and Drug Administration (FDA) has approved hydrocortisone (KHINDIVI) oral solution as a replacement therapy in pediatric patients aged 5 years and older with adrenocortical insufficiency.1Announced by Eton Pharmaceuticals on May 28, 2025, this approval marked the first FDA-approved oral solution formulation of hydrocortisone, designed to address administration and dosing accuracy in patients who may have difficulty swallowing pills or special administration needs.
-
1 month ago | 
hcplive.com | Connor Iapoce
Birtamimab missed the primary endpoint in the Phase 3 AFFIRM-AL clinical trial for the treatment of AL amyloidosis, resulting in the discontinuation of development and the halt of the open-label extension.1Announced by Prothena Corporation on May 23, 2025, the company plans to cut operating costs and significantly shrink its workforce, with further details on the matter expected in June.
-
1 month ago | 
hcplive.com | Connor Iapoce
A systematic literature review of real-world evidence supported the use of baricitinib for the treatment of atopic dermatitis (AD) and alopecia areata (AA), backing similar efficacy and tolerability reported in pivotal clinical trials.1Across 76 publications matching the inclusion criteria, baricitinib, an oral selective Janus kinase 1/2 inhibitor, was linked to a high level of patient satisfaction, particularly for the treatment of itch in AD.
-
1 month ago | 
hcplive.com | Connor Iapoce
The US Food and Drug Administration (FDA) approved treprostinil inhalation powder (YUTREPIA), a prostacyclin analog targeted to improve exercise capability for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).1 Announced by Liquidia Corporation on May 23, 2025, regulatory approval was awarded based on positive data from the Phase 3 INSPIRE trial, in which treprostinil was shown to be safe and well-tolerated...
-
1 month ago | 
hcplive.com | Connor Iapoce
Calprotectin may represent a mechanistically informed biomarker for atherosclerotic cardiovascular disease (ASCVD), with high levels linked to an elevated risk of future cardiac events across 8 years in a new study.1 The diverse, population-based cohort identified the potential biomarker role of circulating calprotectin, irrespective of clinical cardiovascular risk factors, including high-sensitivity C-reactive protein (hs-CRP), N-terminal pro–brain natriuretic peptide (NT-proBNP), and...
-
1 month ago | 
hcplive.com | Connor Iapoce
Olezarsen significantly cut mean triglyceride levels compared with placebo for people with moderate hypertriglyceridemia (HTG) at risk for atherosclerotic cardiovascular disease (ASCVD) in new topline results from the Essence study.1Announced by Ionis Pharmaceuticals, Inc., on May 19, 2025, olezarsen at 80 mg and 50 mg monthly doses achieved a statistically significant ~60% reduction in triglycerides at six months, with most patients returning to normal levels (<150 mg/dL).
-
1 month ago | 
hcplive.com | Connor Iapoce
Fact checked by: Elevated Lp(a) levels are associated with increased risk of recurrent ASCVD events, including myocardial infarction and stroke. The study analyzed data from over 273,000 individuals, confirming that higher Lp(a) levels correlate with increased cardiovascular risk. Intensive LDL-C-lowering therapy, especially with PCSK9 inhibitors, may reduce the adverse effects of high Lp(a) levels.
-
1 month ago | 
hcplive.com | Connor Iapoce
Type 1 diabetes (T1D) development in adulthood was linked to an elevated risk of cardiovascular disease (CVD) and death, with diagnosis at age ≥40 years not related to an improved long-term prognosis compared with those diagnosed earlier.1 The registry-based study, using nationwide Swedish data from 2001 to 2022, identified more than 10,000 people diagnosed with T1D in adulthood between 2001 and 2020 in the National Diabetes Register (NDR), and compared them with approximately 509,000 matched...
